Stoke Therapeutics (STOK) Amortizatization of Intangibles (2021 - 2026)
Stoke Therapeutics (STOK) recorded quarterly Amortizatization of Intangibles of -$365000.0 in Q1 2026, up 33.76% quarter-over-quarter from -$551000.0 in Q4 2025, and up 26.11% on a YoY basis from -$289422.2 in Q1 2025.
Stoke Therapeutics (STOK) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Stoke Therapeutics' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at -$365000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 26.11% year-over-year to -$365000.0; the TTM figure through Mar 2026 stood at -$1.0 million (up 52.46% YoY), while the FY2025 annual figure was -$1.1 million, up 31.0% from the prior year.
- Amortizatization of Intangibles was -$365000.0 for Q1 2026 at Stoke Therapeutics, up from -$551000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $527000.0 in Q2 2025 to a low of -$782000.0 in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged -$216235.3 across 5 years, with a median of -$151000.0 in 2022.
- Biggest YoY gain for Amortizatization of Intangibles was 282.35% in 2025; the steepest drop was 1958.33% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$151000.0 in 2022, then surged by 41.06% to -$89000.0 in 2023, then sank by 778.65% to -$782000.0 in 2024, then advanced by 29.54% to -$551000.0 in 2025, then jumped by 33.76% to -$365000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$365000.0 (Q1 2026), -$551000.0 (Q4 2025), and -$615000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Stoke Therapeutics | 1.89 Bn | 1.89 Bn | - | -365,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -365,000.00 |
| Mar 31, 2026 | -365,000.00 |
| Dec 31, 2025 | -551,000.00 |
| Dec 31, 2025 | -551,000.00 |
| Sep 30, 2025 | -615,000.00 |
| Sep 30, 2025 | -615,000.00 |
| Jun 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 527,000.00 |
| Mar 31, 2025 | -494,000.00 |
| Mar 31, 2025 | -494,000.00 |
| Dec 31, 2024 | -782,000.00 |
| Dec 31, 2024 | -782,000.00 |
| Sep 30, 2024 | -547,000.00 |
| Sep 30, 2024 | -547,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | -24,000.00 |
| Mar 31, 2024 | -24,000.00 |
| Dec 31, 2023 | -89,000.00 |
| Dec 31, 2023 | -89,000.00 |